Optum Didn't Out-Compete UnitedHealthcare. It Bought the People It Pays.

When you fill a prescription through your UnitedHealthcare plan, four things can quietly happen at once: the pharmacy benefit manager is Optum Rx, the analytics scoring your claim is Optum Insight, the doctor who wrote it may be one of roughly 90,000 physicians Optum employs⁷, and the company paying every one of those bills is the same company that owns every one of those vendors. The money never really leaves the building. It just moves from one pocket to another - and on the way, it stops being insurance and starts being profit.

The official story is that Optum is the genius of UnitedHealth: a high-margin services business that quietly outgrew the boring insurance arm and now carries the whole enterprise. That story is half true and dangerously flattering. Optum is not a free-standing champion that out-competed the market. It is the most profitable internal customer relationship in American healthcare - and the buyer and the seller are the same.

Nobody founded Optum. They renamed it.

Start with the origin myth, because it quietly does a lot of work. Optum is often described as if UnitedHealth built a new business from scratch. It didn't. In April 2011 the company took units it already owned - Ingenix, Prescription Solutions, and an existing health-services arm - and put them under one new brand: Optum Insight, Optum Rx, Optum Health.¹ No net-new business was created that day. A holding structure was rebranded. That matters because the entire 'Optum out-grew the insurer' narrative implies an independent contender that won on merit. The truth is closer to a corporation discovering it could charge itself - and then doing so at enormous scale.

Half its revenue is the insurer paying itself

Here is the number that breaks the legend. Optum reported $253 billion in revenue for 2024, up 12% year over year.² Impressive - until you read the footnote. UnitedHealth's own filing discloses corporate eliminations of roughly $150.9 billion for 2024, the majority of which is intercompany revenue flowing from UnitedHealthcare to Optum.⁴ In plain terms: a large slice of Optum's 'revenue' is UnitedHealthcare buying pharmacy services, care delivery, and analytics from a sister company under the same roof. The headline number measures the size of the internal plumbing, not the size of the open market Optum supposedly conquered.

And the price on that internal trade is not set by anyone competing for the business. Per UnitedHealth's 10-K, intercompany transactions between Optum and UnitedHealthcare - pharmacy, care delivery, analytics - are 'recorded at management's estimate of fair value.'⁵ Read that twice. The world's most-cited proof of Optum's competitive brilliance is its margin, and that margin is partly produced by a related-party transfer priced by the very management that benefits from it. It might be perfectly fair. But it is not the market saying so. It is the company saying so about itself.

The profit split nobody quotes correctly

The popular framing says Optum is the dominant engine. The filings say something quieter and more interesting. For full-year 2024, Optum's operating earnings were $16.7 billion²; UnitedHealthcare's were $15.6 billion.³ That is a split of roughly 52/48 - parity, not conquest. Optum earns its profit on a smaller, captive revenue base, so its margins are genuinely better. But 'higher margin on internal volume' and 'beat the market' are not the same claim, and the gap between them is exactly where the story has been oversold.

Why a regulator, not an analyst, is the real tell

The mechanism here is vertical integration: own the insurer, own the pharmacy benefit manager, own the doctors, and capture margin at every handoff a patient passes through. The risk that sits inside that mechanism has a name - self-dealing. If the insurer can steer its members toward the providers it also owns, then 'fair value' becomes whatever keeps the most money inside the family. That is precisely the question the Department of Justice opened a non-public antitrust investigation to answer, reported in early 2024: whether UnitedHealthcare favors Optum-owned physician groups in its contracting, and whether the relationship harms competitors and consumers.⁶ No specific allegations of wrongdoing had been issued as of that reporting. But the investigation is the tell - regulators don't probe businesses that simply earned their margins in open competition. They probe businesses where the buyer and the seller are the same hand.

Isn't Optum just a genuinely better-run business?

The fair objection: maybe Optum really is excellent, and the integration is just how a well-run company lowers its own costs. There's truth in that. Owning the pharmacy benefit manager and the physician groups can cut friction, and Optum's stability proved its worth in 2025, when UnitedHealthcare's operations swung to a loss of $(278) million from $7.8 billion the year before, hit by Medicare funding cuts and rising medical costs.⁸ In that year, Optum was the floor under the whole group. But notice what that actually demonstrates. A diversified arm can stabilize a parent - that's a portfolio argument, not a proof of standalone dominance. And the more indispensable Optum becomes as the earnings floor, the stronger the incentive to keep steering volume and margin toward it, and the sharper the antitrust question gets. Resilience and self-dealing can be the same behavior viewed from two angles. The filing calls it fair value; the regulator calls it a question worth a subpoena.

Optum's genius was never out-competing anyone in the open. It was discovering that a company large enough to be its own customer, its own pharmacy, and its own doctor can decide for itself what each of those services is worth - and book the difference as profit. That works beautifully right up until someone outside the building asks to see the price tag. UnitedHealth built a machine that pays itself. The only open question is whether anyone but UnitedHealth ever got to set the rate.